Skip to content

Observational clinical research on individualized treatment of locally HER2 positive breast cancer patients based on organoid technology

Observational clinical research on individualized treatment of locally HER2 positive breast cancer patients based on organoid technology

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071866
Enrollment
Unknown
Registered
2023-05-26
Start date
2022-11-07
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally HER2 positive breast cancer

Interventions

Locally HER2 positive breast cancer group:No

Sponsors

Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent form; 2. Non-metastatic breast cancer patients whose tumor TNM staging is confirmed by histology is stage II and HER2 positive; 3. Patients with breast cancer diagnosed by tumor thick needle puncture pathology; 4. Cardiac color ultrasound indicates that the cardiac ejection fraction is within the normal range; 5. Eastern Cooperative Oncology Group (ECOG) scale 0-2 points; 6. The organ function is still good and meets the following indicators: Hb >= 90g/L; WBC >= 3.5 x 10^9/L; platelet >= 100 x 10^9/L; neutrophils >= 1.5 x 10^9/L; aspartate aminotransferase = 18 years.

Exclusion criteria

Exclusion criteria: 1. Merge other malignant tumors or have had malignant tumors other than breast cancer in the past 5 years, except for skin basal cell carcinoma or squamous cell carcinoma, and carcinoma in situ of the cervix that have been adequately treated and controlled; 2. Those with active infection who are not suitable for chemotherapy; 3. Severe diseases with non-malignant tumors that affect the patient's compliance or put the patient at risk of chemotherapy; 4. Severe liver dysfunction, Child-Pugh C level; 5. Severe cardiac insufficiency, cardiac function level III or above; 6. Patients with severe renal insufficiency, failure stage and uremia stage.

Design outcomes

Primary

MeasureTime frame
IC50 of drugs acting on organoids;Evaluation of clinical efficacy for breast tumor;

Secondary

MeasureTime frame
Evaluation of clinical pCR;

Countries

China

Contacts

Public ContactLi Yi

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital

liyirx@med.uestc.edu.cn+86 177 0813 0562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026